睿昂基因11月21日获融资买入435.68万元，融资余额5936.47万元

Core Viewpoint - Ruiang Gene experienced a decline of 5.44% in stock price on November 21, with a trading volume of 32.91 million yuan. The financing data indicates a net buying of 2.18 million yuan on that day, while the total financing and securities balance reached 59.36 million yuan, reflecting a low financing balance compared to historical levels [1][2]. Group 1: Company Overview - Ruiang Gene Technology Co., Ltd. was established on February 17, 2012, and went public on May 17, 2021. The company specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments and reagents, primarily focusing on blood diseases, solid tumors, and infectious diseases [2]. - The revenue composition of Ruiang Gene includes 84.23% from self-produced reagents, 6.86% from testing services, 6.63% from purchased reagents, 1.28% from research services, and 1.00% from other sources [2]. Group 2: Financial Performance - For the period from January to September 2025, Ruiang Gene reported an operating income of 139 million yuan, a year-on-year decrease of 26.64%. The net profit attributable to the parent company was -5.62 million yuan, reflecting a significant year-on-year decline of 198.14% [2]. - As of September 30, the number of shareholders for Ruiang Gene was 4,715, an increase of 0.62% from the previous period, while the average circulating shares per person decreased by 0.61% to 11,846 shares [2]. Group 3: Dividend Information - Ruiang Gene has distributed a total of 19.44 million yuan in dividends since its A-share listing [3].